Key facts
- It has raised $29.6M; the latest was Later Stage VC ($14.2M) in Dec 2025.
- Notable investors include Cowin Capital, Xingxiang Investment Holding Group, Challenjers Capital, Jiangsu Xingnahe Investment Management Company, Toutoushidao Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Refine Biology
- ·The full record, as it builds
Funding rounds
No funding rounds for Refine Biology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Refine Biology
Producer of stevia and erythritol intended to develop healthier, aesthetically appealing, functionally enhanced products with reliable safety and regulatory compliance. The company offers non-sugar beverages, stevia and erythritol, thereby providing customers with healthy and tasty goods.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Beijing, China
- Founded
- 2007
- Employees
- 200
- Website
- refinebiology.com/
- Ownership
- Privately Held (backing)
Refine Biology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Refine Biology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Refine Biology in its N-PORT filings yet. We sweep new filings monthly.